Global /United Kingdom /Healthcare /Drug Manufacturers - Specialty & Generic /SBTX
chevron_leftBack
SkinBioTherapeutics plc logo

SkinBioTherapeutics plc

SBTX
LSE: SBTX Delayed
10GBX -4.9%
0.1301 USD
As of 10 June 2026, SkinBioTherapeutics plc has a market cap of $33.71M USD, ranking #33407 globally and #759 in the United Kingdom. It ranks #3015 in the Healthcare sector, and #177 in the Drug Manufacturers - Specialty & Generic industry.
Global Rank
33407
Country Rank
759
Sector Rank
3015
Industry Rank
177
Key Stats
Market Cap
$33.71MUSD
25.27M GBP
Enterprise Value
$28.66MUSD
21.48M GBP
Revenue (TTM)
$6.19MUSD
4.64M GBP
EBITDA (TTM)
-$1.09MUSD
-818.75K GBP
Net Income (TTM)
-$928.73KUSD
-696.25K GBP
EBITDA Margin
-18%
Profit Margin
-15%
PS Ratio
5.4
PB Ratio
2.7
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
CEO
Rachel Parsonage open_in_new
Employees
41
Founded
2015
Website
skinbiotherapeutics.com open_in_new
warningChart data may be delayed
1d 1w 1m 3m 6m 1y
-4.9% 24% 4.6% -38% -36% -59%
Upcoming Earnings
Earnings Date
Tue, Jun 23

News

Loading...

Markets

Exchange Ticker Price
London Stock Exchange
MIC: XLON
PRIMARY
SBTX
SkinBioTherapeutics PLC
ISIN: GB00BF33H870
Shares Out.:
259.169M1 Shares Float: 131.207M2
TV:
SA:
YF:
GF:
BA:
MS:
10 GBX
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.

About SkinBioTherapeutics plc

SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the symptoms associate with psoriasis; and MediBiotix, CleanBiotix, and PharmaBiotix which are in early stages of development. The company has an agreement with Croda Plc for the development of SkinBiotix as an active ingredient for the skicare and cosmetic industry. It serves cosmetic skincare, food supplements, medical skin care, infection control, and pharmaceutical skincare markets. The company was formerly known as Skinbiotix Ltd and changed its name to SkinBioTherapeutics plc in December 2016. SkinBioTherapeutics plc was incorporated in 2015 and is based in Newcastle upon Tyne, the United Kingdom.

Similar Companies

Industry: Drug Manufacturers - Specialty & Generic (United Kingdom)
Name
Market Cap diff.
PE
$3.98B
2.98B GBP
12K%
10.3
$870.04M
652.25M GBP
2K%
-
$716.97M
537.5M GBP
2K%
19.5
$306.7M
229.92M GBP
810%
73.8
IMM
$34.95M
26.2M GBP
3.7%
-
PXS
$32.07M
24.05M GBP
-4.8%
-
Industry: Drug Manufacturers - Specialty & Generic (Global)
Name
Market Cap diff.
PE
$37.19B
108.92B ILS
110K%
24.2
$29.56B
88K%
-
$15.85B
107.34B CNY
47K%
16.0
CIPLA
$11.13B
1.06T INR
33K%
23.4
LUPIN
$11.02B
1.05T INR
33K%
22.7
$9.09B
61.6B CNY
27K%
80.6
chevron_leftBack